The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries

Drug Discovery Today

Volumn 17, Issue 3-4, 2012, Pages 135-142

  Modi, Sandeep ^a   Hughes, Michael ^a   Garrow, Andrew ^a   White, Andrew ^a  

^a UNILEVER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE;

ALGORITHM; AMES TEST; CARCINOGENICITY; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; COMPUTER PROGRAM; DATA EXTRACTION; DATA MINING; DRUG INDUSTRY; DRUG METABOLISM; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPIDOSIS; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; PHYSIOLOGICAL PROCESS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REFERENCE DATABASE; REVIEW; RISK ASSESSMENT; SKIN SENSITIZATION; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; COMPUTER SIMULATION; CONSUMER PRODUCT SAFETY; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 84856508623     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.10.022     Document Type: Review

References (63)

1. P.J. Eddershaw ADME/PK as part of a rational approach to drug discovery Drug Discov. Today 5 2000 409 414 (Pubitemid 30645737)
2. D.A. Smith, and H. Waterbeemd Pharmacokinetics and metabolism in early drug discovery Curr. Opin. Chem. Biol. 3 1999 373 378 (Pubitemid 29376097)
3. J. Wang, and L. Urban The impact of early ADME profiling on drug discovery and development strategy Drug Discov. World Spring 5 2004 73 86
4. R. Schumann The seventh amendment to the cosmetics directive: what does DG enterprise want from ECVAM? Altern. Lab. Anim. 30 Suppl. 2 2002 213 214 (Pubitemid 36168740)
5. I. Kimber Computational chemistry, systems biology and toxicology. Harnessing the chemistry of life: revolutionizing toxicology. A commentary J. Appl. Toxicol. 31 2011 206 209
6. A. Vedani, and M. Smiesko In silico toxicology in drug discovery - concepts based on three-dimensional models Altern. Lab. Anim. 37 2009 477 496
7. S. Modi Positioning ADMET in silico tools in drug discovery Drug Discov. Today 9 2004 14 15 (Pubitemid 38169025)
8. H. Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat. Drug Discov. Rev. 2 2003 192 204 (Pubitemid 37361664)
9. M. Dickins, and S. Modi Importance of predictive ADME simulations Drug Discov. Today 7 2002 755 756
10. M. Cronin Use of QSARs in international decision-making frameworks to predict health effects of chemical substances Environ. Health Perspect. 111 2003 1391 1401 (Pubitemid 37021144)
11. T.I. Netzeva Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52 Altern. Lab. Anim. 33 2005 155 173 (Pubitemid 40686385)
12. T. Hartung Food for thought on animal tests ALTEX 25 2008 3 9
13. T. Hartung Toxicology for the 21st century Nature 460 2009 208 212
14. D.E. Clark In silico ADMET tools: the dawn of a new generation? Expert Opin. Drug Discov. 2 2007 1423 1429 (Pubitemid 350186595)
15. A. Williams Free online resources enabling crowd-sourced drug discovery Drug Discov. World 10 2010 33 39
16. D. Fourches Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research J. Chem. Inf. Model. 50 2010 1189 1204
17. J. Kazius Derivation and validation of toxicophores for mutagenicity prediction J. Med. Chem. 48 2005 312 320 (Pubitemid 40105270)
18. T.W. Schultz Verification of the structural alerts for Michael acceptors Chem. Res. Toxicol. 20 2007 1359 1363 (Pubitemid 47548304)
19. L.G. Valerio In silico toxicology for the pharmaceutical sciences Toxicol. Appl. Pharmacol. 241 2009 356 370
20. P.N. Judson Using computer reasoning about qualitative and quantitative information to predict metabolism and toxicity B. Testa, Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies 2006 Wiley 183 215
21. T.W. Schultz The present status of QSAR in toxicology J. Mol. Struct. Theochem. 622 2003 23 38
22. N.F. Cariello Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity Mutagenesis 17 2002 321 329 (Pubitemid 34814654)
23. E. Benfenati Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives J. Environ. Sci. Health C: Environ. Carcinog. Ecotoxicol. Rev. 27 2009 57 90
24. K. Hansen Benchmark data set for in silico prediction of Ames mutagenicity J. Chem. Inf. Model. 49 2009 2077 2081
25. P. Mazzatorta Modeling oral rat chronic toxicity J. Chem. Inf. Model. 48 2008 1949 1954
26. J. Bercu In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances Regul. Toxicol. Pharmacol. 57 2010 300 306
27. S.R. Vink Use of read-across and tiered exposure assessment in risk assessment under REACH - a case study on a phase-in substance Regul. Toxicol. Pharmacol. 58 2010 64 71
28. C. Yang Understanding genetic toxicity through data mining: the process of building knowledge by integrating multiple genetic toxicity databases Toxicol. Mech. Methods 18 2008 277 295 (Pubitemid 351414968)
29. J. Bajorath Virtual screening in drug discovery: methods, expectations and reality Curr. Drug Discov. 2 2002 24 28 (Pubitemid 34269451)
30. T. Nonoyama, and R. Fukuda Drug-induced phospholipidosis - pathological aspects and its prediction J. Toxicol. Pathol. 21 2008 9 24
31. P. Crivori, and I. Poggesi Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs Eur. J. Med. Chem. 41 2006 795 808 (Pubitemid 44015977)
32. H. Li Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction J. Comput. Aided Mol. Des. 22 2008 843 855
33. L. Michielan, and S. Moro Pharmaceutical perspectives of nonlinear QSAR strategies J. Chem. Inf. Model. 50 2010 961 978
34. Q. Li hERG classification model based on a combination of support vector machine method and GRIND descriptors Mol. Pharm. 5 2008 117 127 (Pubitemid 351300041)
35. C.L. Gavaghan Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data J. Comput. Aided Mol. Des. 21 2007 189 206 (Pubitemid 46510843)
36. J. Jaworska QSAR applicability domain estimation by projection of the training set descriptor space: a review Altern. Lab. Anim. 33 2005 445 459 (Pubitemid 41613738)
37. R.W. Stanforth A measure of domain of applicability for QSAR modelling based on intelligent K-means clustering QSAR Comb. Sci. 26 2007 837 846
38. H. Dragos Predicting the predictability: a unified approach to the applicability domain problem of QSAR models J. Chem. Inf. Comput. Sci. 49 2009 1762 1777
39. J. Bentzien An in silico method for predicting ames activities of primary aromatic amines by calculating the stabilities of nitrenium ions J. Chem. Inf. Model. 50 2010 274 297
40. S. Kar, and K. Roy QSAR modeling of toxicity of diverse organic chemicals to Daphnia magna using 2D and 3D descriptors J. Hazard. Mater. 177 2010 344 351
41. L. Eriksson Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs Environ. Health Perspect. 111 2003 1361 1367
42. A. Tropsha The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models QSAR Comb. Sci. 22 2003 69 79
43. T. Abshear A model validation and consensus building environment SAR QSAR Environ. Res. 17 2006 311 321 (Pubitemid 44034666)
44. E.J. Mathews Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data Curr. Drug Discov. Technol. 1 2004 61 76
45. N. Baurin 2D QSAR consensus prediction for high-throughput virtual screening. An application to COX-2 inhibitionmodeling and screening of the NCI database J. Chem. Inf. Comput. Sci. 44 2004 276 285
46. R. Guha, and S.C. Schürer Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays J. Comput. Aided Mol. 22 2008 367 384
47. T.R. Stouch In silico ADME/Tox: why models fail J. Comput. Aided Mol. Des. 17 2003 83 92 (Pubitemid 37069196)
48. T.A. Baillie Drug metabolites in safety testing Toxicol. Appl. Pharmacol. 182 2002 188 196
49. United States Food and Drug Administration: Center for Drug Evaluation and, Research Guidance for Industry Safety Testing of Drug Metabolites 2008
50. D.A. Smith, and R.S. Obach Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing Drug Metab. Dispos. 33 2005 1409 1417 (Pubitemid 41323986)
51. G. Cruciani Integrating crystallography into early metabolism studies J.L. Sussman, P. Spadon, From Molecules to Medicine 2009 Springer Science 63 77
52. W.G. Button Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics J. Chem. Inf. Comput. Sci. 43 2003 1371 1377
53. S. Boyer Reaction site mapping of xenobiotic biotransformations J. Chem. Inf. Model. 47 2007 583 590 (Pubitemid 46615959)
54. M.T.D. Cronin In silico toxicology challenges for pharmaceuticals: complacency or controversy? Altern. Lab. Anim. 37 2009 453 456
55. H. Raunio In silico toxicology - non-testing methods Front. Pharmacol. 2 2011 1 8
56. S. Modi Computational approaches to the understanding of ADMET properties and problems Drug Discov. Today 8 2003 621 623 (Pubitemid 36809256)
57. J. Fostel Predictive ADME-Tox Expert Opin. Drug Metabol. Toxicol. 1 2005 565 570
58. N. Parrott Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man Basic Clin. Pharmacol. Toxicol. 96 2005 193 199 (Pubitemid 40387995)
59. D. Rotroff Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by toxcast chemicals J. Toxicol. Environ. Health B: Crit. Rev. 13 2010 1329 1346
60. C.W. Schmidt TOX 21: new dimensions of toxicity testing Environ. Health Perspect. 117 2009 A348 A353
61. M. Andersen, and D. Krewski Toxicity testing in the 21st century: bringing the vision to life Tox. Sci. 107 2009 324 330
62. T.B. Knudsen Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets Toxicology 282 2011 1 15
63. I. Shah Virtual tissues in toxicology J. Toxicol. Environ. Health B: Crit. Rev. 13 2010 314 328